Lazard Asset Management
NTLA icon

Lazard Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Lazard Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Sell
84,379
-9,241
-10% -$129K ﹤0.01% 1108
2026
Q1 		$1.2M Sell
93,620
-5,144
-5% -$65.5K ﹤0.01% 1104
2025
Q4 		$888K Sell
98,764
-15,850
-14% -$218K ﹤0.01% 1193
2025
Q3 		$1.98M Buy
114,614
+22,184
+24% +$273K ﹤0.01% 860
2025
Q2 		$866K Sell
92,430
-15,627
-14% -$128K ﹤0.01% 1345
2025
Q1 		$768K Sell
108,057
-1,443
-1% -$14.6K ﹤0.01% 1298
2024
Q4 		$1.28M Buy
109,500
+7,488
+7% +$117K ﹤0.01% 1048
2024
Q3 		$2.1M Sell
102,012
-14,378
-12% -$332K ﹤0.01% 862
2024
Q2 		$2.6M Buy
116,390
+26,332
+29% +$627K ﹤0.01% 813
2024
Q1 		$2.48M Sell
90,058
-12,175
-12% -$338K ﹤0.01% 803
2023
Q4 		$3.12M Sell
102,233
-3,917
-4% -$113K ﹤0.01% 778
2023
Q3 		$3.35M Sell
106,150
-1,329
-1% -$51.6K ﹤0.01% 780
2023
Q2 		$4.38M Buy
107,479
+1,021
+1% +$41.4K 0.01% 730
2023
Q1 		$3.97M Buy
106,458
+58,951
+124% +$2.31M 0.01% 774
2022
Q4 		$1.66M Sell
47,507
-39,889
-46% -$1.9M ﹤0.01% 927
2022
Q3 		$4.89M Buy
87,396
+4,971
+6% +$308K 0.01% 719
2022
Q2 		$4.27M Buy
82,425
+81,876
+14,914% +$4.16M 0.01% 765
2022
Q1 		$39K Buy
549
+146
+36% +$12.4K ﹤0.01% 1860
2021
Q4 		$47K Buy
403
+393
+3,930% +$49.2K ﹤0.01% 1767
2021
Q3 		$1K Buy
+10
New +$1.51K ﹤0.01% 2131

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Lazard Asset Management's NTLA Position: Q2 2026 in Review

Lazard Asset Management reduced its Intellia Therapeutics (NTLA) stake by 9.9% in Q2 2026, selling an estimated $129K and leaving 84,379 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Lazard Asset Management first reported a position in NTLA in Q3 2021 and has held it in 20 quarters since. The position peaked at $4.89M in Q3 2022. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Lazard Asset Management held 84,379 shares of Intellia Therapeutics worth $1.43M as of Q2 2026.
  • Lazard Asset Management sold 9,241 Intellia Therapeutics shares in Q2 2026, an estimated $129K.
  • Intellia Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1108 holding.
  • Lazard Asset Management first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Lazard Asset Management's Intellia Therapeutics position peaked at $4.89M in Q3 2022.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.